Bookmark and Share
BioAssay: AID 651904

Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response counterscreen assay to determine cytotoxicity of test compounds

Name: Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response counterscreen assay to determine cytotoxicity of test compounds. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Inactive(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Inactive(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 651904
Data Source: The Scripps Research Institute Molecular Screening Center (U2OSCTYOX_INH_LUMI_384_4XEC50)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2012-12-11
Hold-until Date: 2013-06-17
Modify Date: 2013-06-17

Data Table ( Complete ):           All
Tested Compound:
Depositor Specified Assays
Show more
AIDNameTypeComment
504355Summary of the probe development efforts to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorssummarySummary (OPRM1 and OPRD1 agonists)
504326Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsscreeningPrimary screen (OPRM1 and OPRD1 agonists in singlicate).
504692Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)screeningCounterscreen (HTR5A agonists in singlicate)
504904Luminescence-based cell-based high throughput confirmation assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsscreeningConfirmation screen (OPRM1-OPRD1 agonists in triplicate)
504905Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)screeningCounterscreen (HTR5A agonists in triplicate)
588407Luminescence-based cell-based high throughput dose response assay for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptorsconfirmatoryDose response assay (OPRM1-OPRD1 agonists in triplicate)
588408Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based high throughput dose response assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)confirmatoryDose response counterscreen assay (HTR5A agonists in triplicate)
588411Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRD1 homodimerizationconfirmatoryDose response counterscreen assay (OPRD1 agonists in triplicate)
588435Counterscreen for agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors: Luminescence-based cell-based high throughput dose response assay to identify agonists of OPRM1 homodimerizationconfirmatoryDose response counterscreen assay (OPRM1 agonists in triplicate)
651685Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assayconfirmatoryLate-stage dose response (OPRM1 and OPRD1 heterodimer formation activators in triplicate or quadruplicate)
651686Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreenconfirmatoryLate-stage dose response counterscreen (OPRD1 activators in triplicate or quadruplicate)
651688Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response HTR5A counterscreenconfirmatoryLate-stage dose response counterscreen (HTR5A activators in triplicate or quadruplicate)
651689Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRM1 counterscreenconfirmatoryLate-stage dose response counterscreen (OPRM1 activators in triplicate or quadruplicate)
651762Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response assay, Set 2confirmatoryLate-stage dose response (OPRM1 and OPRD1 heterodimer formation activators in triplicate)
651764Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRD1 counterscreen, Set 2confirmatoryLate-stage dose response counterscreen (OPRD1 activators in triplicate)
651765Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response HTR5A counterscreen, Set 2confirmatoryLate-stage dose response counterscreen (HTR5A activators in triplicate)
651769Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response OPRM1 counterscreen, Set 2confirmatoryLate-stage dose response counterscreen (OPRM1 activators in triplicate)
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center (SRIMSC)
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Lakshmi A. Devi, Mount Sinai School of Medicine
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: R03NS053751
Grant Proposal PI: Lakshmi A. Devi, Mount Sinai School of Medicine
External Assay ID: U2OSCTYOX_INH_LUMI_384_4XEC50

Name: Late-stage results from the probe development effort to identify activators of OPRM1 and OPRD1 heterodimer formation: luminescence-based cell-based dose response counterscreen assay to determine cytotoxicity of test compounds.

Description:

Opiates such as morphine are the choice analgesic in the treatment of chronic pain due to their potent and rapid action. However, their long-term use is limited because of the development of tolerance and dependence, as well as respiratory suppression and constipation (1). Due to their clinical importance, various strategies have been considered for making opiates more effective while curbing liabilities such as addiction. One such strategy has been to use a combination of drugs to improve the effectiveness of morphine. The OPRM1 gene encodes the mu opioid receptor, which is the primary site of action for morphine (2) and other commonly used opioid such as heroin, fentanyl, and methadone. OPRM1 activation and subsequent dissociation of the Gi/Go G-proteins results in reduction of adenylyl cyclase-mediated cAMP production (3). There are at least two other types of opioid receptors: delta (OPRD1) and kappa (OPRK1), each with a distinct pharmacologic profile. In particular, delta (OPRD1) opioid receptor ligands have been useful in enhancing morphine's potency, but the underlying molecular basis is not understood (4). It has been shown that modulation of receptor function by physical association between mu and delta opioid receptors is a potential mechanism (5). The assay provider has previously found that a combination of OPRM1 agonist with OPRD1 antagonist selectively activates the OPRM1-OPRD1 heteromer (5) and recently showed that this could be blocked by antibodies that selectively recognize the heteromer (6). Since OPRD1 antagonist have anxiogenic effects, these are not ideal as therapies. Hence, the identification of compounds that selectively activate mu-delta opioid receptor heterodimerization may have potential in the treatment of pain and alleviate unwanted effects associated with opiate use.

References:

1. Raehal KM, Bohn LM. Mu opioid receptor regulation and opiate responsiveness. AAPS J. 2005 Oct 19;7(3):E587-91.
2. Matthes H, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dolle P, Tzavara E, Hanoune J, Roques B, Kieffer B (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819-823.
3. Maguea SD and Blendy JAOPRM1 SNP (A118G): Involvement in disease development, treatment response, and animal models. Drug and Alcohol Dependence. 2010 May 108 (3): 172-182.
4. Traynor J, Elliot J. Delta-opioid receptor subtypes and cross talk with mu-receptors. Trends Pharmacol Sci 1993 14:84-86.
5. Gomes I, Jordan BA, Gupta A, Trapaidze N, Nagy V, Devi LA. Heterodimerization of mu and delta opioid receptors: A role in opiate synergy. J Neurosci. 2000 Nov 15;20(22):RC110.
6. Gupta, A., Mulder, J., Gomes, I., Rozenfeld, R., Bushlin, I., Ong, E., Lim, M., Maillet, E., Junek, M., Cahill, C.M., Harkany, T. Devi, L.A. Increased abundance of opioid receptor heteromers after chronic morphine administration. Science Signaling 3:ra54, 2010

Keywords:

Late stage, late stage AID, powders, OPRD1, delta, OPRM1, mu, heterodimer, opioid, receptor, GPCR, PathHunter, U2OS, luminescence, cytotoxicity, CellTitre-Glo, CC50, holoenzyme, agonist, activator, pain, Deltorphin B, 384, dose response, Scripps, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Protocol
Assay Overview:

The purpose of this assay is to determine cytotoxicity of powder compounds that activate heterodimer formation between the mu (OPRM1) and delta (OPRD1) opioid receptors. In this assay, U2OS cells are incubated with test compound, followed by determination of cell viability. The assay utilizes the CellTiter-Glo luminescent reagent to measure intracellular ATP in viable cells. Luciferase present in the reagent catalyzes the oxidation of beetle luciferin to oxyluciferin and light in the presence of cellular ATP. Well luminescence is directly proportional to ATP levels and cell viability. As designed, compounds that reduce cell viability will reduce ATP levels, luciferin oxidation and light production, resulting in decreased well luminescence. Compounds were tested in quadruplicate in a 13-point 1:3 dilution series starting at a nominal test concentration of 10 uM.

Protocol Summary:

This assay was started by dispensing PathHunter trade mark OPRM1/D1-Beta-Arrestin U20S cells in McCoy's 5A medium plus 10% FBS, penicillin 100 U/mL and streptomycin 100 ug/mL (20 uL, 4 x 10E3 cells/well) into the wells of a 384-well plate. Thirteen 1:3 serial dilutions of compound (100 uM in growth media) were made. 5 uL of diluted compound or media were added to wells, giving final compound concentrations of 0-10 uM. The plate was incubated at 37 C in a humidified incubator for 24 hours, then equilibrated to room temperature for 30 minutes. 25 uL CellTitre-Glo reagent was added to each well, followed by incubation of the plate in the dark for 10 minutes. Well luminescence was measured on the Envision plate reader.

The % Cell Viability for each well was then calculated as follows:

%_Cell_Viability = 1 - ( MedianRFU_High_Control - RFU_Test_Compound ) / ( MedianRFU_High_Control - MedianRFU_Low_Control ) * 100

Where:

Test_Compound is defined as wells containing cells in the presence of test compound.
High_Control is defined as wells containing cells treated with media only (no compound).
Low_Control is defined as wells containing no cells (media only).

Percent Cell Viability was plotted against the log of the compound concentration. The CC50 is reported as ">X uM" (where X = the highest concentration tested for which >50% Cell Viability was observed).

PubChem Activity Outcome and Score:

Compounds with a CC50 value equal to or less than of less than 10 uM were considered active (cytotoxic). Compounds with a CC50 value greater than 10 uM were considered inactive (non-cytotoxic).

Activity score was then ranked by the potency of the compounds with fitted curves, with the most potent compounds assigned the highest activity scores.

The PubChem Activity Score range for inactive compounds is 0-0. There are no active compounds.

List of Reagents:

PathHunter trade mark OPRM1/D1-Beta-Arrestin U20S Cell Line (Discover X, part 93-0558C3)
McCoy's 5A Medium (Invitrogen, part 16600-082)
FBS (Invitrogen, part 26140-079)
Penicillin / Streptomycin (Invitrogen, part 15140-122)
Cell Titer-Glo (Promega, part G7572)
384-well plates (Corning 3570)
Comment
This assay was performed by the SRIMSC with powder samples of test compounds.
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1QualifierActivity Qualifier identifies if the resultant data CC50 came from a fitted curve or was determined manually to be less than or greater than its listed CC50 concentration.String
2CC50*The value for concentration at which 50% of surviving cells are observed; CC50 shown in micromolar.FloatμM
3Viability at 10 uM [1] (10μM**)Viability at 10 uM compound concentration; replicate [1]Float%
4Viability at 10 uM [2] (10μM**)Viability at 10 uM compound concentration; replicate [2]Float%
5Viability at 10 uM [3] (10μM**)Viability at 10 uM compound concentration; replicate [3]Float%
6Viability at 10 uM [4] (10μM**)Viability at 10 uM compound concentration; replicate [4]Float%
7Viability at 3.33 uM [1] (3.33μM**)Viability at 3.33 uM compound concentration; replicate [1]Float%
8Viability at 3.33 uM [2] (3.33μM**)Viability at 3.33 uM compound concentration; replicate [2]Float%
9Viability at 3.33 uM [3] (3.33μM**)Viability at 3.33 uM compound concentration; replicate [3]Float%
10Viability at 3.33 uM [4] (3.33μM**)Viability at 3.33 uM compound concentration; replicate [4]Float%
11Viability at 1.11 uM [1] (1.11μM**)Viability at 1.11 uM compound concentration; replicate [1]Float%
12Viability at 1.11 uM [2] (1.11μM**)Viability at 1.11 uM compound concentration; replicate [2]Float%
13Viability at 1.11 uM [3] (1.11μM**)Viability at 1.11 uM compound concentration; replicate [3]Float%
14Viability at 1.11 uM [4] (1.11μM**)Viability at 1.11 uM compound concentration; replicate [4]Float%
15Viability at 0.37 uM [1] (0.37μM**)Viability at 0.37 uM compound concentration; replicate [1]Float%
16Viability at 0.37 uM [2] (0.37μM**)Viability at 0.37 uM compound concentration; replicate [2]Float%
17Viability at 0.37 uM [3] (0.37μM**)Viability at 0.37 uM compound concentration; replicate [3]Float%
18Viability at 0.37 uM [4] (0.37μM**)Viability at 0.37 uM compound concentration; replicate [4]Float%
19Viability at 0.123 uM [1] (0.123μM**)Viability at 0.123 uM compound concentration; replicate [1]Float%
20Viability at 0.123 uM [2] (0.123μM**)Viability at 0.123 uM compound concentration; replicate [2]Float%
21Viability at 0.123 uM [3] (0.123μM**)Viability at 0.123 uM compound concentration; replicate [3]Float%
22Viability at 0.123 uM [4] (0.123μM**)Viability at 0.123 uM compound concentration; replicate [4]Float%
23Viability at 0.0411 uM [1] (0.0411μM**)Viability at 0.0411 uM compound concentration; replicate [1]Float%
24Viability at 0.0411 uM [2] (0.0411μM**)Viability at 0.0411 uM compound concentration; replicate [2]Float%
25Viability at 0.0411 uM [3] (0.0411μM**)Viability at 0.0411 uM compound concentration; replicate [3]Float%
26Viability at 0.0411 uM [4] (0.0411μM**)Viability at 0.0411 uM compound concentration; replicate [4]Float%
27Viability at 0.0137 uM [1] (0.0137μM**)Viability at 0.0137 uM compound concentration; replicate [1]Float%
28Viability at 0.0137 uM [2] (0.0137μM**)Viability at 0.0137 uM compound concentration; replicate [2]Float%
29Viability at 0.0137 uM [3] (0.0137μM**)Viability at 0.0137 uM compound concentration; replicate [3]Float%
30Viability at 0.0137 uM [4] (0.0137μM**)Viability at 0.0137 uM compound concentration; replicate [4]Float%
31Viability at 0.00457 uM [1] (0.00457μM**)Viability at 0.00457 uM compound concentration; replicate [1]Float%
32Viability at 0.00457 uM [2] (0.00457μM**)Viability at 0.00457 uM compound concentration; replicate [2]Float%
33Viability at 0.00457 uM [3] (0.00457μM**)Viability at 0.00457 uM compound concentration; replicate [3]Float%
34Viability at 0.00457 uM [4] (0.00457μM**)Viability at 0.00457 uM compound concentration; replicate [4]Float%
35Viability at 0.00152 uM [1] (0.00152μM**)Viability at 0.00152 uM compound concentration; replicate [1]Float%
36Viability at 0.00152 uM [2] (0.00152μM**)Viability at 0.00152 uM compound concentration; replicate [2]Float%
37Viability at 0.00152 uM [3] (0.00152μM**)Viability at 0.00152 uM compound concentration; replicate [3]Float%
38Viability at 0.00152 uM [4] (0.00152μM**)Viability at 0.00152 uM compound concentration; replicate [4]Float%
39Viability at 0.000508 uM [1] (0.000508μM**)Viability at 0.000508 uM compound concentration; replicate [1]Float%
40Viability at 0.000508 uM [2] (0.000508μM**)Viability at 0.000508 uM compound concentration; replicate [2]Float%
41Viability at 0.000508 uM [3] (0.000508μM**)Viability at 0.000508 uM compound concentration; replicate [3]Float%
42Viability at 0.000508 uM [4] (0.000508μM**)Viability at 0.000508 uM compound concentration; replicate [4]Float%
43Viability at 0.000169 uM [1] (0.000169μM**)Viability at 0.000169 uM compound concentration; replicate [1]Float%
44Viability at 0.000169 uM [2] (0.000169μM**)Viability at 0.000169 uM compound concentration; replicate [2]Float%
45Viability at 0.000169 uM [3] (0.000169μM**)Viability at 0.000169 uM compound concentration; replicate [3]Float%
46Viability at 0.000169 uM [4] (0.000169μM**)Viability at 0.000169 uM compound concentration; replicate [4]Float%
47Viability at 0.0000565 uM [1] (5.65e-05μM**)Viability at 0.0000565 uM compound concentration; replicate [1]Float%
48Viability at 0.0000565 uM [2] (5.65e-05μM**)Viability at 0.0000565 uM compound concentration; replicate [2]Float%
49Viability at 0.0000565 uM [3] (5.65e-05μM**)Viability at 0.0000565 uM compound concentration; replicate [3]Float%
50Viability at 0.0000565 uM [4] (5.65e-05μM**)Viability at 0.0000565 uM compound concentration; replicate [4]Float%
51Viability at 0.0000188 uM [1] (1.88e-05μM**)Viability at 0.0000188 uM compound concentration; replicate [1]Float%
52Viability at 0.0000188 uM [2] (1.88e-05μM**)Viability at 0.0000188 uM compound concentration; replicate [2]Float%
53Viability at 0.0000188 uM [3] (1.88e-05μM**)Viability at 0.0000188 uM compound concentration; replicate [3]Float%
54Viability at 0.0000188 uM [4] (1.88e-05μM**)Viability at 0.0000188 uM compound concentration; replicate [4]Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: R03NS053751

Data Table (Concise)
PageFrom: